

Special Issue

Biomarkers for Inflammatory and Metabolic Disorders

Message from the Guest Editors

We are pleased to invite you to submit to this new Special Issue, entitled “Biomarkers for Inflammatory and Metabolic Disorders”, of the *Journal of Personalized Medicine*, which highlights the most recent findings concerning to result of biomarkers, development and the role of many factors such as nutrition, diet and the development of rare diseases. The search for biomarkers, particularly in relation to rare diseases, is one of the key goals of personalized medicine and this field is progressing rapidly. Especially important, the development and deployment of high-throughput techniques, combining basic and clinical research, provide an opportunity to speed up the appropriate validation of biomarkers and may potentially contribute to the reduction in diagnostic costs in the future. Therefore, we assume that the presented articles will highlight the latest achievements and clinical utility of biomarkers in the assessment of disease and in clinical follow-up.

Guest Editors

Dr. Aldona Wierzbicka

Department of Biochemistry and Experimental Medicine, Children's Memorial Health Institute, Warsaw, Poland

Dr. Joanna B. Bierła

Department of Pathomorphology, Children's Memorial Health Institute, Al. Dzieci Polskich 20, 04-730 Warsaw, Poland

Deadline for manuscript submissions

closed (1 June 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed




mdpi.com/si/175598

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).